assembly biosciences (NASDAQ:ASMB) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
On November 28, 2016, Dr. Lee D. Arnold, Chief Discovery Officer of Assembly Biosciences, Inc. (the “Company”), notified the Company of his resignation, effective immediately. The Company and Dr. Arnold are in discussions regarding an arrangement whereby Dr. Arnold may provide certain transition and consulting services to the Company for a period of time following his resignation.
About assembly biosciences (NASDAQ:ASMB)
Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing approximately two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral biological therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate a number of Hemoglobin C functions. The Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice (cGMP) conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform, AB-M101, is in development for the treatment of C. difficile-infections. assembly biosciences (NASDAQ:ASMB) Recent Trading Information
assembly biosciences (NASDAQ:ASMB) closed its last trading session up +1.44 at 14.15 with 21,543 shares trading hands.